Fagron NV
Research Fagron NV (FAGR) on Bullrun: market cap EUR 1.65B, P/E 18.0, dividend yield 1.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFAGR
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.65B
- P/E18.0
- Dividend yield1.8%
- Financial periodFY2025
- RevenueEUR 952.17M
- Revenue growth9.2%
- Net incomeEUR 91.02M
- Free cash flowEUR 124.64M
- Gross margin45.4%
Valuation Snapshot
latest market cap is EUR 1.65B; P/E is 18.0; dividend yield is 1.8%.
Peer valuation comparison
Latest P/E is 17.96x versus a Healthcare sector median of 24.46x (26.6% below).
Latest dividend yield is 1.78% versus a Healthcare sector median of 2.11% (15.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 952.17M | EUR 91.02M | EUR 124.64M | 45.4% | 1.24 | EUR 184.90M | EUR 468.23M | EUR 551.58M |
| FY2024 | EUR 871.96M | EUR 80.55M | EUR 69.10M | 45.4% | 1.1 | EUR 115.04M | EUR 385.70M | EUR 501.35M |
| FY2023 | EUR 762.99M | EUR 70.55M | EUR 86.16M | 43.6% | 0.97 | EUR 133.01M | EUR 366.74M | EUR 463.72M |
| FY2022 | EUR 683.88M | EUR 69.61M | EUR 90.96M | 41.8% | 0.96 | EUR 125.34M | EUR 399.38M | EUR 404.54M |
| FY2021 | EUR 573.81M | EUR 61.38M | n/a | 58.6% | 0.84 | EUR 70.65M | EUR 297.38M | EUR 325.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | EUR 1.65B | 18.0 | 1.8% | 0.4 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.4 EUR, yield 1.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.35 EUR |
| FY2024 | 0.3 EUR |
| FY2023 | 0.25 EUR |
| FY2022 | 0.2 EUR |
| FY2021 | 0.18 EUR |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fagron NV's market cap?
Fagron NV's market capitalization is EUR 1.65B.
What is Fagron NV's P/E ratio?
Fagron NV's price-to-earnings (P/E) ratio is 18.0.
Does Fagron NV pay a dividend?
Fagron NV has a dividend yield of 1.8%.
What does Fagron NV do?
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services.